The DOI matches its Crossref record; 914 of the 914 references it cites were found in a registry or an index.
Human prostate cancer risk factors
Open accessAbstract
Prostate cancer has the highest prevalence of any nonskin cancer in the human body, with similar likelihood of neoplastic foci found within the prostates of men around the world regardless of diet, occupation, lifestyle, or other factors. Essentially all men with circulating androgens will develop microscopic prostate cancer if they live long enough. This review is a contemporary and comprehensive, literature-based analysis of the putative risk factors for human prostate cancer, and the results were presented at a multidisciplinary consensus conference held in Crystal City, Virginia, in the fall of 2002. The objectives were to evaluate known environmental factors and mechanisms of prostatic carcinogenesis and to identify existing data gaps and future research needs. The review is divided into four sections, including 1) epidemiology (endogenous factors [family history, hormones, race, aging and oxidative stress] and exogenous factors [diet, environmental agents, occupation and other factors, including lifestyle factors]); 2) animal and cell culture models for prediction of human risk (rodent models, transgenic models, mouse reconstitution models, severe combined immunodeficiency syndrome mouse models, canine models, xenograft models, and cell culture models); 3) biomarkers in prostate cancer, most of which have been tested only as predictive factors for patient outcome after treatment rather than as risk factors; and 4) genotoxic and nongenotoxic mechanisms of carcinogenesis. The authors conclude that most of the data regarding risk relies, of necessity, on epidemiologic studies, but animal and cell culture models offer promise in confirming some important findings. The current understanding of biomarkers of disease and risk factors is limited. An understanding of the risk factors for prostate cancer has practical importance for public health research and policy, genetic and nutritional education and chemoprevention, and prevention strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–800 of 914
Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11.
Rinker-Schaeffer, C. W., Hawkins, A. L., Ru, N., Dong, J., Stoica, G., Griffin, C. A., Ichikawa, T., Barrett, J. C., & Isaacs, J. T. (1994) · PubMed · Cited by 86
Tea and other beverage consumption and prostate cancer risk: a Canadian retrospective cohort study
Ellison, L. F. (2000) · European Journal of Cancer Prevention · doi:10.1097/00008469-200004000-00009 · Cited by 86
Qian, J., Hirasawa, K., Bostwick, D. G., Bergstralh, E. J., Slezak, J. M., Anderl, K. L., Borell, T. J., Lieber, M. M., & Jenkins, R. B. (2002) · Modern Pathology · doi:10.1038/modpathol.3880487 · Cited by 86
Self-citationCowen, D. M., Troncoso, P., Khoo, V. S., Zagars, G. K., von Eschenbach, A. C., Meistrich, M. L., & Pollack, A. S. (2002) · PubMed · Cited by 86
Charles, L. E. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg044 · Cited by 85
Vorherr, H., Messer, R. H., Vorherr, U. F., Jordan, S. W., & Kornfeld, M. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90638-5 · Cited by 85
Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion
Jarrard, D. F., Blitz, B. F., Smith, R. C., Patai, B., & Rukstalis, D. B. (1994) · The Prostate · doi:10.1002/pros.2990240110 · Cited by 85
Gsur, A. (2002) · Carcinogenesis · doi:10.1093/carcin/23.10.1647 · Cited by 85
Androgen-regulated gene expression in prostate cancer
Trapman, J., & Cleutjens, K. B. J. M. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0050 · Cited by 85
Corder, E. H., FRIEDMAN, G. D., Vogelman∥, J. H., & Orentreich∥, N. (1995) · PubMed · Cited by 85
Sebo, T. J., Cheville, J. C., Riehle, D., Lohse, C. M., Pankratz, V. S., Myers, R. P., Blute, M. L., & Zincke, H. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200204000-00004 · Cited by 85
Myers, J. C., Li, D., Bageris, A., Abraham, V., Dion, A. S., & Amenta, P. S. (1997) · Europe PMC (PubMed Central) · Cited by 84
Prostate cancer in pesticide applicators in Swedish agriculture
Dich, J., & Wiklund, K. (1998) · The Prostate · Cited by 84
Wang, Q. F., Tilly, K. I., Tilly, J. L., Preffer, F. I., Schneyer, A. L., Crowley, W. F., & Sluss, P. M. (1996) · Endocrinology · doi:10.1210/endo.137.12.8940374 · Cited by 84
Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China
Lacey, J. V., Deng, J., Dosemeci, M., Gao, Y., Mostofi, F. K., Sesterhenn, I. A., Xie, T., & Hsing, A. W. (2001) · International Journal of Epidemiology · doi:10.1093/ije/30.2.341 · Cited by 84
Clarke, G., & Whittemore, A. S. (2000) · PubMed · Cited by 83
植野, 修., & WEIGEL, N. L. (2002) · Journal of Andrology · doi:10.1002/j.1939-4640.2002.tb02596.x · Cited by 82
Milovanović, S. R., Radulovic, S. S., Groot, K., & Schally, A. V. (1992) · The Prostate · doi:10.1002/pros.2990200403 · Cited by 82
Deftos, L. J., Nakada, S. Y., Burton, D. W., di Sant'Agnese, P. A., Cockett, A. T. �., & Abrahamsson, P.-A. (1996) · Urology · doi:10.1016/s0090-4295(96)00089-1 · Cited by 82
Autochthonous mouse models for prostate cancer: past, present and future
Huss, W. J., Maddison, L. A., & Greenberg, N. M. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0373 · Cited by 82
Potter, S. R., Miller, M. C., Mangold, L. A., et al. (1999) · Urology · doi:10.1016/s0090-4295(99)00328-3 · Cited by 82
Jenkins, R. B., Takahashi, S., Delacey, K. A., Bergstralh, E. J., & Lieber, M. M. (1998) · PubMed · Cited by 82
Connolly, J. M., & Rose, D. P. (1989) · The Prostate · doi:10.1002/pros.2990150211 · Cited by 81
Bodiwala, D., Luscombe, C. J., Liu, S., Saxby, M. F., French, M., Jones, P. W., Fryer, A. A., & Strange, R. C. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00710-3 · Cited by 81
Parental Age at Child's Birth and Son's Risk of Prostate Cancer: The Framingham Study
Zhang, Y., Kreger, B. E., Dorgan, J. F., Cupples, L. A., Myers, R. H., Splansky, G. L., Schatzkin, A. G., & Ellison, R. C. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009947 · Cited by 81
Investigation into the Mechanism of the Loss of Laminin 5 (α3β3γ2) Expression in Prostate Cancer
Hao, J., Jackson, L., Calaluce, R., McDaniel, K. M., Dalkin, B. L., & Nagle, R. B. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64060-6 · Cited by 81
The Role of the Androgen Receptor in Prostate Cancer
Huang, H., & Tindall, D. J. (2002) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.v12.i3.30 · Cited by 81
Song, Z., Wu, X., Powell, W. C., Cardiff, R. D., Cohen, M. B., Tin, R. T., Matusik, R. J., Miller, G. J., & Roy‐Burman, P. (2002) · PubMed · Cited by 81
Oh, B. R., Sasaki, M., PERINCHERY, G., Ryu, S. B., Park, Y. I., Carroll, P. R., & Dahiya, R. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67683-5 · Cited by 81
Dixon, S. C., Soriano, B. J., Lush, R. M., et al. (1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100113 · Cited by 81
Gallee, M. P. W., Jong, E. V.-D., ten Kate, F. J. W., Schroeder, F. H., & van der Kwast, T. (1989) · The Journal of Urology · doi:10.1016/s0022-5347(17)39094-8 · Cited by 81
Fudge, K., Bostwick, D. G., & Stearns, M. E. (1996) · The Prostate · Cited by 80
Self-citationPolychronakos, C., Janthly, U., Lehoux, J., et al. (1991) · The Prostate · doi:10.1002/pros.2990190405 · Cited by 80
Brinkmann, A. O., Jenster, G. W., Ris‐Stalpers, C., van der Korput, J. A. G. M., Brüggenwirth, H. T., Boehmer, A. L. M., & Trapman, J. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00090-m · Cited by 79
Qian, J., Jenkins, R. B., & Bostwick, D. G. (1999) · European Urology · doi:10.1159/000019883 · Cited by 79
Self-citationKaaks, R., Lukanova, A., Rinaldi, S., Biessy, C., Söderberg, S., Olsson, T., Stenman, U.-H., Ríboli, E., Hallmans, G., & Stattin, P. (2003) · European Journal of Cancer Prevention · doi:10.1097/00008469-200308000-00011 · Cited by 79
HER2 Protein Expression and Gene Amplification in Androgen-Independent Prostate Cancer
Reese, D., Small, E. J., Magrane, G., Waldman, F. M., Chew, K., & Sudilovsky, D. (2001) · American Journal of Clinical Pathology · doi:10.1309/vxkk-yvrh-9b11-ydpt · Cited by 79
Prostate cancer progression, metastasis, and gene expression in transgenic mice.
Perez‐Stable, C., Altman, N. H., Mehta, P. P., Deftos, L. J., & Roos, B. A. (1997) · PubMed · Cited by 78
DNA base modifications and antioxidant enzyme activities in human benign prostatic hyperplasia
Oliński, R., Zastawny, T. H., Foksiński, M., Barecki, A., & Dizdaroğlu, M. (1995) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(94)00171-f · Cited by 78
Alcohol Use and Prostate Cancer Risk in US Blacks and Whites
Hayes, R. B., Brown, L. M., Schoenberg, J. B., Greenberg, R. S., Silverman, D. T., Schwartz, A. G., Swanson, G. M., Bénichou, J., Liff, J. M., Hoover, R. N., et al. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008802 · Cited by 78
Cvetković, D., Movsas, B., Dicker, A. P., Hanlon, A. L., Greenberg, R. E., Chapman, J. D., Hanks, G. E., & Tricoli, J. V. (2001) · Urology · doi:10.1016/s0090-4295(00)01044-x · Cited by 78
Thomas, T. Z., Wang, H., Niclasen, P., O’Bryan, M. K., Evans, L. W., Groome, N. P., Pedersen, J., & Risbridger, G. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.11.4374 · Cited by 78
Montironi, R., Magi‐Galluzzi, C., Muzzonigro, G., Prete, E., Polito, M., & Fabris, G. (1994) · Journal of Clinical Pathology · doi:10.1136/jcp.47.10.906 · Cited by 77
The Development of Casodex™ (Bicalutamide): Preclinical Studies
Furr, B. J. A. (1996) · European Urology · doi:10.1159/000473846 · Cited by 76
Kallakury, B., Sheehan, C. E., & Ross, J. S. (2001) · Human Pathology · doi:10.1053/hupa.2001.26463 · Cited by 76
HYYTINEN, E.-R., Haapala, K., Thompson, J. S., Lappalainen, I., Roiha, M., Rantala, I. S., Helin, H. J., Jänne, O. A., Vihinen, M., Palvimo, J. J., et al. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000038924.67707.75 · Cited by 76
Kwak, C. H., Jin, R., Lee, C. H., Park, M. S., & Lee, S. E. (2002) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.01417.x · Cited by 75
Antioxidant Enzymes In Malignant Prostate Cell Lines and In Primary Cultured Prostatic Cells
Jung, K., Seidel, B., Rudolph, B. D., Lein, M., Cronauer, M. V., Henke, W., Hampel, G., Schnorr, D., & Loening, S. A. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00613-2 · Cited by 75
Epidemiology of High-Grade Prostatic Intraepithelial Neoplasia
Sakr, A. W., Billis, A., Ekman, P., Wilt, T. J., & Bostwick, D. G. (2000) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/003655900750169275 · Cited by 75
Self-citationKöllermann, J. W., & Helpap, B. (2001) · American Journal of Clinical Pathology · doi:10.1309/1lbm-6x32-jh6w-enud · Cited by 75
CHANGES IN COLLAGEN METABOLISM IN PROSTATE CANCER
Burns‐Cox, N., Avery, N. C., Gingell, J. C., & Bailey, A. J. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65656-x · Cited by 75
Isaacs, J. T. (1984) · PubMed · Cited by 75
Hanada, K., Perry-Lalley, D. M., Ohnmacht, G. A., Bettinotti, M. P., & Yang, J. C.-H. (2001) · PubMed · Cited by 75
Confirmation of Linkage of Prostate Cancer Aggressiveness with Chromosome 19q
Slager, S. L., Schaid, D. J., Cunningham, J. M., McDonnell, S. K., Marks, A. F., Peterson, B. J., Hebbring, S. J., Anderson, S., French, A. J., & Thibodeau, S. N. (2003) · The American Journal of Human Genetics · doi:10.1086/368230 · Cited by 74
Androgen receptor CAG polymorphism and prostate cancer risk
Mononen, N., Ikonen, T., Autio, V., Rökman, A., Matikainen, M. P., Tammela, T. L. J., Kallioniemi, O., Koivisto, P. A., & Schleutker, J. (2002) · Human Genetics · doi:10.1007/s00439-002-0776-5 · Cited by 74
Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study
Sesso, H. D., Paffenbarger, R. S., & Lee, I. (2001) · International Journal of Epidemiology · doi:10.1093/ije/30.4.749 · Cited by 74
Androgen receptor polymorphisms and the incidence of prostate cancer.
Chen, C., Lamharzi, N., Weiss, N. S., Etzioni, R., Dightman, D. A., Barnett, M. J., diTommaso, D., & Goodman, G. E. (2002) · PubMed · Cited by 74
Hartman, T. J., Albanes, D., Rautalahti, M., Tangrea, J. A., Virtamo, J. R. K., Stolzenberg, R., & Taylor, P. R. (1998) · Cancer Causes & Control · doi:10.1023/a:1008889001519 · Cited by 73
Glynne-Jones, E., Goddard, L., & Harper, M. E. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90399-8 · Cited by 73
Ghadirian, P., Lacroix, A., Maisonneuve, P., Perret, C., Drouin, G., Perrault, J.-P., B�land, G., Rohan, T. E., & Howe, G. R. (1996) · Cancer Causes & Control · doi:10.1007/bf00052669 · Cited by 73
Jenkins, R. B., Takahashi, S., Delacey, K. A., Bergstralh, E. J., & Lieber, M. M. (1998) · Genes Chromosomes and Cancer · Cited by 73
Molecular markers for predicting prostate cancer stage and survival
Dunsmuir, W. D., Gillett, C., Meyer, L., Young, M., Corbishley, C. M., Eeles, R. A., & Kirby, R. S. (2000) · British Journal of Urology · doi:10.1046/j.1464-410x.2000.00916.x · Cited by 72
Henrard, D. R., & Ross, S. R. (1988) · Journal of Virology · doi:10.1128/jvi.62.8.3046-3049.1988 · Cited by 72
Sexual factors and prostate cancer
Giles, G., Severi, G., English, D., Mccredie, M., Borland, R., Boyle, P., & Hopper, J. (2003) · BJU International · doi:10.1046/j.1464-410x.2003.04319.x · Cited by 72
Webber, M. M., Bello, D., Kleinman, H. K., Wartinger, D. D., Williams, D. E., & Rhim, J. S. (1996) · Carcinogenesis · doi:10.1093/carcin/17.8.1641 · Cited by 72
Kramer, G., Steiner, G. E., Födinger, D., Fiebiger, E., Rappersberger, C., Binder, S., Hofbauer, J., & Marberger, M. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)66733-8 · Cited by 72
Cancer therapy and prevention by green tea: role of ornithine decarboxylase
Bachrach, U., & Wang, Y.-C. (2002) · Amino Acids · doi:10.1007/s726-002-8197-9 · Cited by 72
The Urokinase-type Plasminogen Activator System in Prostate Cancer Metastasis
Sheng, S. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1015539612576 · Cited by 71
The role of diet in prostate cancer
Kaul, L., Heshmat, M. Y., Kovi, J., Jackson, M. A., Jackson, A. G., Jones, G. W., Edson, M., Enterline, J. P., Worrell, R. G., & Perry, S. L. (1987) · Nutrition and Cancer · doi:10.1080/01635588709513919 · Cited by 71
Claudio, P. P., Zamparelli, A., Garcia, F. U., Claudio, L., Ammirati, G., Farina, A., Bovicelli, A., Russo, G. M., Giordano, G. G., McGinnis, D. E., et al. (2002) · PubMed · Cited by 71
Miyoshi, Y., Uemura, H., Fujinami, K., Mikata, K., Harada, M., Kitamura, H., Koizumi, Y., & Kubota, Y. (2000) · The Prostate · Cited by 71
AMINES, ANTICONVULSANTS, AND EPILEPSY
Chadwick, D., Jenner, P., & Reynolds, E. H. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92639-2 · Cited by 71
Chetcuti, A., Margan, S. H., Mann, S., Russell, P., Handelsman, D. J., Rogers, J. H., & Dong, Q. (2001) · The Prostate · doi:10.1002/pros.1056 · Cited by 70
Androgen Receptor Length Polymorphism Associated with Prostate Cancer Risk in Hispanic Men
Balic, I., GRAHAM, S. T., Troyer, D. A., Higgins, B., Pollock, B. H., Johnson‐Pais, T. L., Thompson, I. M., & Leach, R. J. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64364-9 · Cited by 70
Kawana, Y., Komiya, A., Ueda, T., Nihei, N., Kuramochi, H., Suzuki, H., Yatani, R., Imai, T., Dong, J., Imai, T., et al. (1997) · The Prostate · Cited by 70
Valve, E. M., Nevalainen, M. T., Nurmi, M. J., Laato, M. K., MARTIKAINEN, P. M., & HARKONEN, P. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780291 · Cited by 70
Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145
McPherson, S. J., Thomas, T. Z., Wang, H., Gurusinghe, C. J., & Risbridger, G. P. (1997) · Journal of Endocrinology · doi:10.1677/joe.0.1540535 · Cited by 70
Lein, M., Jung, K., Ortel, B. J., Stephan, C., Rothaug, W., Juchem, R., Johannsen, M., Değer, S., Schnorr, D., Loening, S. A., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205267 · Cited by 70
Human Androgen Receptor Expression in Prostate Cancer following Androgen Ablation
White, R. D., Meyers, F. J., Chi, S.-G., Chamberlain, S., Siders, D. B., Lee, F., STEWART, S. L., & Gumerlock, P. H. (1997) · European Urology · doi:10.1159/000474409 · Cited by 70
Leav, I., Schelling, K. H., Adams, J. Y., Merk, F. B., & Alroy, J. (2001) · The Prostate · doi:10.1002/pros.1100 · Cited by 70
Bone morphogenetic protein-6 expression in normal and malignant prostate
Barnes, J., Anthony, C. T., Wall, N. A., et al. (1995) · World Journal of Urology · doi:10.1007/bf00191214 · Cited by 69
Epner, D. E., Partin, A. W., Schalken, J. A., Isaacs, J. T., & Coffey, D. S. (1993) · PubMed · Cited by 69
Raghow, S., Kuliyev, E., Steakley, M., Greenberg, N. M., & Steiner, M. S. (2000) · PubMed · Cited by 68
Čulig, Z., Hobisch, A., Hittmair, A., Cronauer, M. V., Radmayr, C., Bartsch, G. H., & Klocker, H. (1997) · Drugs & Aging · doi:10.2165/00002512-199710010-00005 · Cited by 68
Genetic predisposition to prostate cancer
Eeles, R. A., the UK Familial Prostate Study Co-ordinating Group, & Collaborators, T. C. U. F. P. C. S. (1999) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500279 · Cited by 68
Hyytinen, E.-R., Thalmann, G., Zhau, H. E., Karhu, R., Kallioniemi, O., Chung, L. W. K., & Visakorpi, T. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.32 · Cited by 68
Occupation, physical activity, and risk of prostate cancer in Shanghai, People's Republic of China
Hsing, A. W., McLaughlin, J. K., Zheng, W., Gao, Y., & Blot, W. J. (1994) · Cancer Causes & Control · doi:10.1007/bf01830259 · Cited by 66
Leung, S. Y. L., Jackson, J. K., Miyake, H., Burt, H. M., & Gleave, M. E. (2000) · The Prostate · doi:10.1002/1097-0045(20000701)44:2<144::aid-pros7>3.0.co;2-g · Cited by 66
Sadi, M. V., & Barrack, E. R. (1991) · Cancer · doi:10.1002/1097-0142(19910615)67:12<3065::aid-cncr2820671222>3.0.co;2-u · Cited by 66
Impact of Smoking on Cancer Stage at Diagnosis
Kobrinsky, N. L., Klug, M. G., Hokanson, P. J., Sjolander, D. E., & Burd, L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.110 · Cited by 65
Pflug, B. R., & Djakiew, D. (1998) · Molecular Carcinogenesis · Cited by 65
Self-citationPlasma prolactin and prostate cancer risk: A prospective study
Stattin, P., Rinaldi, S., Stenman, U., Ríboli, E., Hallmans, G., Bergh, A. R. J., & Kaaks, R. (2001) · International Journal of Cancer · doi:10.1002/ijc.1191 · Cited by 64
Control Response Proportions in Population-Based Case-Control Studies in Germany
Stang, A., Ahrens, W., & Jöckel, K. (1999) · Epidemiology · doi:10.1097/00001648-199903000-00017 · Cited by 64
Alterations of the retinoblastoma gene in human prostate adenocarcinoma
Tricoli, J. V., Gumerlock, P. H., Yao, J. L., Chi, S., D'Souza, S. A., Nestok, B. R., & White, R. D. (1996) · Genes Chromosomes and Cancer · Cited by 64
Vitamin A and prostate cancer in elderly men: enhancement of risk.
Kolonel, L. N., Hankin, J. H., & YOSHIZAWA, C. N. (1987) · PubMed · Cited by 63
Zinc potentiation of androgen receptor binding to nuclei in vitro
Colvard, D. S., & Wilson, E. M. (1984) · Biochemistry · doi:10.1021/bi00310a014 · Cited by 63
Down-regulation of beta 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma.
Fornaro, M., Tallini, G., Bofetiado, C. J. M., Bòsari, S., & Languino, L. R. (1996) · Europe PMC (PubMed Central) · Cited by 62
Family aggregation of cancer of the prostate in quebec: The tip of the iceberg
Ghadirian, P., Cadotte, M., Lacroix, A., & Perret, C. (1991) · The Prostate · doi:10.1002/pros.2990190105 · Cited by 62
Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma
Brothman, A. R., Lesho, L. J., Somers, K. D., Wright, G. L., & Merchant, D. J. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910440525 · Cited by 62
Klein, R. D. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.217 · Cited by 62
Bichât, F., Gonfalone, G., Bras-Gonçalves, R., Dutrillaux, B., & Poupon, M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.274 · Cited by 61
Diabetes Mellitus and the Risk of Prostate Cancer
Rosenberg, D. J., Neugut, A. I., Ahsan, H., & Shea, S. (2002) · Cancer Investigation · doi:10.1081/cnv-120001141 · Cited by 61
Bruckheimer, E. M., & Kyprianou, N. (2001) · Endocrinology · doi:10.1210/endo.142.6.8218 · Cited by 61
Response of rat and human prostatic cancers to the novel 5α‐reductase inhibitor, SK&F 105657
Lamb, J. C., Isaacs, J. T., Levy, M. A., & Johnson, R. K. (1992) · The Prostate · doi:10.1002/pros.2990210103 · Cited by 61
Huss, W. J., Barrios, R. J., Foster, B. A., & Greenberg, N. M. (2002) · The Prostate · doi:10.1002/pros.10163 · Cited by 61
Response of prostate cancer cells to peptide growth factors: transforming growth factor-beta.
Wilding, G. (1991) · PubMed · Cited by 61
Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma.
Quarmby, V. E., Beckman, W. C., Cooke, D. B., et al. (1990) · PubMed · Cited by 60
Dalkin, A. C., Gilrain, J. T., Bradshaw, D., & Myers, C. E. (1996) · Endocrinology · doi:10.1210/endo.137.12.8940339 · Cited by 60
Urokinase-Type Plasminogen Activator Expression in Human Prostate Carcinomas
Veldhuizen, P. J. V., Sadasivan, R., Cherian, R., & Wyatt, A. (1996) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)41739-2 · Cited by 60
Percutaneous Cryoablation of the Prostate: Preliminary Results After 95 Procedures
Coogan, C. L., & McKiel, C. F. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)66791-0 · Cited by 60
Occupational physical activity and risk for prostate cancer in a nationwide cohort study in Sweden
Norman, A., Moradi, T., Gridley, G., Dosemeci, M., Rydh, B., Nyrén, O., & Wolk, A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600023 · Cited by 60
Androgen-receptor gene structure and function in prostate cancer
Hakimi, J. M., Rondinelli, R. H., Schoenberg, M., & Barrack, E. R. (1996) · World Journal of Urology · doi:10.1007/bf00184606 · Cited by 60
P53 and Ki‐67 Immunoreactivity in Human Prostate Cancer and Benign Hyperplasia
Thompson, S., Mellon, K., Charlton, R., Marsh, C., Robinson, M., & Neal, D. E. (1992) · British Journal of Urology · doi:10.1111/j.1464-410x.1992.tb15632.x · Cited by 60
Loop, S. M., Rozanski, T. A., & Ostenson, R. C. (1993) · The Prostate · doi:10.1002/pros.2990220202 · Cited by 60
ANDROGEN RECEPTOR EXPRESSION IN PROSTATIC INTRAEPITHELIAL NEOPLASIA AND CANCER
SWEAT, S. D., Pacelli, A., Bergstralh, E. J., et al. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)61644-6 · Cited by 60
Dietary vitamin a and cancer—a Multisite case‐control study
Blackford Middleton, A., Byers, T., Marshall, J. R., & Graham, S. (1986) · Nutrition and Cancer · doi:10.1080/01635588609513883 · Cited by 59
Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis
Chevalier, S., Defoy, I., Lacoste, J., Hamel, L., Guy, L., Bégin, L. R., & Aprikian, A. G. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00728-6 · Cited by 59
Frequency and characterization of p53 mutations in clinically localized prostate cancer
Hall, M. C., Navone, N. M., Troncoso, P., Pollack, A. S., Zagars, G. K., von Eschenbach, A. C., Conti, C. J., & Chung, L. W. K. (1995) · Urology · doi:10.1016/s0090-4295(99)80018-1 · Cited by 59
5 alpha-reductase activity and prostate cancer: a case-control study using stored sera.
Guess, H. A., FRIEDMAN, G. D., Sadler, M., Stanczyk, F. Z., Vogelman∥, J. H., Imperato‐McGinley, J., Lobo, R., & Orentreich∥, N. (1997) · PubMed · Cited by 59
Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk.
Zheng, S. L., Chang, B., Faith, D., Johnson, J. R., Isaacs, S. D., Hawkins, G. A., Turner, A. R., Wiley, K. E., Bleecker, E. R., Walsh, P. C., et al. (2002) · PubMed · Cited by 58
Dj, G., & Eh, H. (1995) · PubMed · Cited by 58
Balaji, K. C., Koul, H., Mitra, S., Maramag, C., Reddy, P., Menon, M., Kaur Malhotra, R., & Laxmanan, S. (1997) · Urology · doi:10.1016/s0090-4295(97)00390-7 · Cited by 57
Tseng, Y., Hong, R., Tao, M., & Chang, F. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990301)80:5<704::aid-ijc13>3.0.co;2-z · Cited by 57
Hellawell, G. O., Ferguson, D. J. P., BREWSTER, S. F., & Macaulay, V. M. (2003) · British Journal of Urology · doi:10.1046/j.1464-410x.2003.04061.x · Cited by 57
Dairy Products and the Risk of Prostatic Cancer
Vecchia, C. L., Negri, E., D’Avanzo, B., Franceschi, S., & Boyle, P. (2009) · Oncology · doi:10.1159/000226970 · Cited by 57
Silencing of CD44 Expression in Prostate Cancer by Hypermethylation of the CD44 Promoter Region
Verkaik, N. S., van Steenbrugge, G. J., van Weerden, W. M., Bussemakers, M. J. G., & van der Kwast, T. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780137 · Cited by 57
Takahashi, S., Alcaraz, A., Brown, J. A., Borell, T. J., Herath, J. F., Bergstralh, E. J., Lieber, M. M., & Jenkins, R. B. (1996) · PubMed · Cited by 57
Joseph, I. B. J., Vukanovic, J., & Isaacs, J. T. (1996) · PubMed · Cited by 56
Yokoyama, Y., Green, J. E., Sukhatme, V. P., & Ramakrishnan, S. (2000) · PubMed · Cited by 56
Ho, S., & Roy, D. (1994) · Cancer Letters · doi:10.1016/0304-3835(94)90370-0 · Cited by 55
Self-citationAn in vivo model of prostate carcinoma growth and invasion in bone
Fisher, J., Schmitt, J. F., Howard, M. L., et al. (2002) · Cell and Tissue Research · doi:10.1007/s00441-001-0503-x · Cited by 55
Ritchie, P. K., Spangelo, B. L., Krzymowski, D. K., Rossiter, T. B., Kurth, E. J., & Judd, A. M. (1997) · Cytokine · doi:10.1006/cyto.1996.0153 · Cited by 55
Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models.
Bosland, M. C. (1996) · PubMed · Cited by 55
Rajan, R., Vanderslice, R., Kapur, S., Lynch, J. H., Thompson, E. W., & Djakiew, D. (1996) · The Prostate · Cited by 54
Self-citationGenetic Alterations of Androgen Receptor Gene in Japanese Human Prostate Cancer
Watanabe, M., Ushijima, T., Shiraishi, T., Yatani, R., Shimazaki, J., Kotake, T., Sugimura, T., & Nagao, M. (1997) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/27.6.389 · Cited by 53
Skalnik, D. G., Dorfman, D. M., Perkins, A. S., Jenkins, N. A., Copeland, N. G., & Orkin, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8505 · Cited by 53
Alcohol consumption and risk of prostate cancer
Tavani, A., Negri, E., Franceschi, S., Talamini, R., & Vecchia, C. L. (1994) · Nutrition and Cancer · doi:10.1080/01635589409514301 · Cited by 53
Inhibition of Prostate Tumor Angiogenesis by the Tumor Suppressor CEACAM1
Volpert, O. V., Luo, W., Liu, T.-J., Estrera, V. T., Logothetis, C. J., & Lin, S.-H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205319200 · Cited by 53
Establishment and Characterization of a Human Primary Prostatic Adenocarcinoma Cell Line (ND-1)
Narayan, P. A., & Dahiya, R. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)36978-1 · Cited by 52
Cigarette smoking and risk of prostate cancer in the physicians' health study (United States)
Lotufo, P. A., Lee, I., Ajani, U. A., Hennekens, C. H., & Manson, J. E. (2000) · International Journal of Cancer · Cited by 52
Lifestyle factors and insulin-like growth factor 1 levels among elderly men
Signorello, L. B., Kuper, H., Λάγιου, Π., Wuu, J., Mucci, L. A., Trichopoulos, D., & Adami, H. (2000) · European Journal of Cancer Prevention · doi:10.1097/00008469-200006000-00004 · Cited by 52
Biochemistry of prostate specific antigen, PSA
Malm, J., & Lilja, H. G. (1995) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365519509090559 · Cited by 52
Levine, A. C., Wang, J. P., Ren, M., Eliashvili, E., Russell, D. W., & Kirschenbaum, A. M. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550782 · Cited by 52
Molecular Characterization of the Human trk OncogenePreprint
Martı́n-Zanca, D., Mitra, G., Long, L. K., & Barbacid, M. (1986) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1986.051.01.112 · Cited by 52
EXPRESSION OF THE VEGF-RECEPTOR Flt-1 IN BENIGN, PREMALIGNANT AND MALIGNANT PROSTATE TISSUES
HAHN, D., Simak, R., Steiner, G., Handisurya, A., Susani, M., & Marberger, M. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67414-9 · Cited by 52
Story, M. T., Hopp, K. A., Molter, M., & Meier, D. A. (1994) · Growth Factors · doi:10.3109/08977199409010993 · Cited by 52
Breslow, R., Wideroff, L., Graubard, B., Erwin, D., Reichman, M., Ziegler, R., & Ballard-Barbash, R. (1999) · Annals of Epidemiology · doi:10.1016/s1047-2797(98)00071-4 · Cited by 52
Involvement of the Multiple Tumor Suppressor Genes and 12-Lipoxygenase in Human Prostate Cancer
Gao, X., Porter, A. T., & Honn, K. V. (1997) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-1813-0_7 · Cited by 51
NOBLE, R. L., & Hoover, L. (1975) · PubMed · Cited by 51
Thomas, T. Z., Chapman, S. M., Wang, H., Gurusingfhe, C., Mellor, S. L., Fletcher, R. J., Pedersen, J., & Risbridger, G. P. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(19980101)34:1<34::aid-pros5>3.0.co;2-k · Cited by 51
Experimental studies of apocrine secretion in the dorsal prostate epithelium of the rat
Aum�ller, G., & Adler, G. (1979) · Cell and Tissue Research · doi:10.1007/bf00234842 · Cited by 51
Elo, J. P., Härkönen, P. K., Kyllönen, A. P., Lukkarinen, O. A., & Vihko, P. (1998) · British Journal of Cancer · doi:10.1038/sj.bjc.6690025 · Cited by 51
Linkage analysis of prostate cancer susceptibility: confirmation of linkage at 8p22–23
Wiklund, F. E., Jonsson, B., Göransson, I., Bergh, A. R. J., & Grönberg, H. (2003) · Human Genetics · doi:10.1007/s00439-003-0916-6 · Cited by 50
Radiation-induced neoplastic transformation of human prostate epithelial cells.
Kuettel, M. R., Thraves, P. J., Jung, M., Varghese, S., Prasad, S. C., Rhim, J. S., & Dritschilo, A. (1996) · PubMed · Cited by 49
The Role of Bcl-2 Expression in EGF Inhibition of TNF-α/IFN-γ-induced Villous Trophoblast Apoptosis
Ho, S., Winkler‐Lowen, B., Morrish, D. W., Dakour, J., Li, H., & Guilbert, L. J. (1999) · Placenta · doi:10.1053/plac.1999.0394 · Cited by 49
Self-citationExpression and regulation of steroid 5 alpha-reductase in the urogenital tract of the fetal rat
Berman, D. M., Tian, H., & Russell, D. W. (1995) · Molecular Endocrinology · doi:10.1210/mend.9.11.8584033 · Cited by 49
International comparison on ras gene mutations in latent prostate carcinoma
Watanabe, M., Shiraishi, T., Yatani, R., Nomura, A. M. Y., & Stemmermann, G. N. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580205 · Cited by 49
Establishment of new human prostatic cancer cell line (JCA-I)
Muraki, J., Addonizio, J. C., Choudhury, M. S., Fischer, J., Eshghi, M., Davidian, M. M., Shapiro, L. R., Wilmot, P. L., Nagamatsu, G. R., & Chiao, J. W. (1990) · Urology · doi:10.1016/0090-4295(90)80319-i · Cited by 49
Rat prostatic steroid binding protein: DNA sequence and transcript maps of the two C3 genes.
Hurst, H. C., & Parker, M. G. (1983) · The EMBO Journal · doi:10.1002/j.1460-2075.1983.tb01498.x · Cited by 48
Udayakumar, T. S., Stratton, M. S., Nagle, R. B., & Bowden, G. T. (2002) · Neoplasia · doi:10.1038/sj.neo.7900207 · Cited by 48
Miguel, M. P. D., Royuela, M., de Bethencourt, F. R., Santamarı́a, L., Fraile, B., & Paniagua, R. T. (2000) · Cytokine · doi:10.1006/cyto.1999.0585 · Cited by 48
PROSTATIC LEVELS OF FATTY ACIDS AND THE HISTOPATHOLOGY OF LOCALIZED PROSTATE CANCER
Freeman, V. L., Meydani, M., Yong, S. L., Pyle, J. M., Flanigan, R. C., Waters, W. B., & Wojcik, E. M. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)66991-1 · Cited by 48
Polymorphisms in the androgen receptor and type II 5α‐reductase genes and prostate cancer prognosis
Shibata, A., García, M. I., Cheng, I. C., Stamey, T. A., McNeal, J. E., Brooks, J. D., Henderson, S. S., Yemoto, C., & Peehl, D. M. (2002) · The Prostate · doi:10.1002/pros.10119 · Cited by 48
Familial study of prostate cancer in Jamaica
Glover, F. E., Coffey, D. S., Douglas, L. L., Russell, H. E., Cadigan, M., Tulloch, T., Wedderburn, K., Wan, R. L., Baker, T. D., & Walsh, P. C. (1998) · Urology · doi:10.1016/s0090-4295(98)00200-3 · Cited by 48
Dirx, M. J. M. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.6.530 · Cited by 47
Rosini, P., Bonaccorsi, L., Baldi, E., Chiasserini, C., Forti, G., Chiara, G. D., Lucibello, M., Mongiat, M., Iozzo, R. V., Garaci, E., et al. (2002) · The Prostate · doi:10.1002/pros.10164 · Cited by 47
Hardell, L., Degerman, A., Tomić, R., Marklund, S. L., & Bergfors, M. (1995) · European Journal of Cancer Prevention · doi:10.1097/00008469-199502000-00009 · Cited by 47
Telomerase Activity in Human Benign Prostate Tissue and Prostatic Adenocarcinomas
Kallakury, B., Brien, T. P., Lowry, C. V., Muraca, P. J., Fisher, H. A. G., Kaufman, R. P., & Ross, J. S. (1997) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199708000-00003 · Cited by 47
Prostate cancer screening (United States)
Waterbor, J. W., & Bueschen, A. J. (1995) · Cancer Causes & Control · doi:10.1007/bf00051798 · Cited by 46
Velasco, A., Hewitt, S. M., Albert, P. S., Saboorian, M. H., Rosenberg, H., Martínez, C., Sagalowsky, A. I., McConnell, J. D., Linehan, W. M., & Leach, F. S. (2002) · Cancer · doi:10.1002/cncr.10247 · Cited by 46
Miyagi, T., Hori, O., Koshida, K., Egawa, M., KATO, H., Kitagawa, Y., Ozawa, K., Ogawa, S., & Namiki, M. (2002) · International Journal of Urology · doi:10.1046/j.1442-2042.2002.00519.x · Cited by 46
Telomerase reverse transcriptase subunit immunoreactivity
Iczkowski, K. A., Pantazis, C. G., McGregor, D. H., Wu, Y., & Tawfik, O. W. (2002) · Cancer · doi:10.1002/cncr.10988 · Cited by 46
Benign Prostatic Hyperplasia: Pathogenesis and Medical Therapy
Geller, J. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb03576.x · Cited by 46
Hayes, R. B., de Jong, F. H., Raatgever, J. W., Bogdanoviczi, J., Schroeder, F. H., der Maas, P., Oishi, K., & Yoshida, O. (1992) · European Journal of Cancer Prevention · doi:10.1097/00008469-199204000-00005 · Cited by 46
Hsing, A. W., Chokkalingam, A. P., Gao, Y. T., Wu, G., Wang, X., Deng, J., Cheng, J., Sesterhenn, I. A., Mostofi, F. K., Chiang, T.-Y., et al. (2002) · PubMed · Cited by 46
Mehta, P. B., Robson, C. N., Neal, D. E., & Leung, H. Y. (2001) · Oncogene · doi:10.1038/sj.onc.1204688 · Cited by 45
Increased Phospholipid Fatty Acid Remodeling in Human and Rat Prostatic Adenocarcinoma Tissues
Faas, F. H., Dang, A. Q., Pollard, M., Hong, X., Fan, K., Luckert, P. H., & Schütz, M. (1996) · The Journal of Urology · doi:10.1016/s0022-5347(01)66009-9 · Cited by 45
Association of E-cadherin germ-line alterations with prostate cancer.
Ikonen, T., Matikainen, M. P., Mononen, N., HYYTINEN, E.-R., Helin, H. J., Tommola, S., Tammela, T. L. J., Pukkala, ., Schleutker, J., Kallioniemi, O., et al. (2001) · PubMed · Cited by 45
Chromatin texture signatures in nuclei from prostate lesions.
Bartels, P. H., da Silva, V. D., Montironi, R., Hamilton, P. W., Thompson, D., Vaught, L. E., & Bartels, H. G. (1998) · PubMed · Cited by 45
Lifetime occupational physical activity and incidental prostate cancer (Canada)
Bairati, I., Larouche, R., Meyer, F., Moore, L., & Fradet, Y. (2000) · Cancer Causes & Control · doi:10.1023/a:1008936826337 · Cited by 44
Lahtonen, R. (1985) · The Prostate · doi:10.1002/pros.2990060208 · Cited by 44
del Rosario, A. D., Bui, H. X., Abdulla, M., & Ross, J. S. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90210-8 · Cited by 44
Estrogenic and DNA-Damaging Activity of Red No. 3 in Human Breast Cancer Cells
Dees, C., Askari, M., Garrett, S. H., Gehrs, K., Henley, D. C., & Ardies, C. M. (1997) · Environmental Health Perspectives · doi:10.1289/ehp.97105s3625 · Cited by 44
Tandem CAG Repeats of the Androgen Receptor Gene and Prostate Cancer Risk in Black and White Men
Panz, V. R., Joffe, B. I., Spitz, I. M., Lindenberg, T., Farkas, A., & Haffejee, M. (2001) · Endocrine · doi:10.1385/endo:15:2:213 · Cited by 44
An adjustment to the 1997 estimate for new prostate cancer cases
Wingo, P. A., Landis, S., & Ries, L. A. G. (1997) · Cancer · Cited by 44
Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Kimura, N., Hoshi, S., Takahashi, M., et al. (1997) · PubMed · Cited by 44
A novel human cell culture model for the study of familial prostate cancer.
Yasunaga, Y., Nakamura, K., Ewing, C. M., et al. (2001) · PubMed · Cited by 43
Oncogene amplifications in early‐stage human prostate carcinomas
Latil, A., Jc, B., Cussenot, O., Fournier, G., BOCCON-GIBOD, L., Duc, A. L., & Lidereau, R. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590510 · Cited by 43
Suzuki, H., Akakura, K., Komiya, A., Ueda, T., Imamoto, T., Furuya, Y., Ichikawa, T., Watanabe, M., Shiraishi, T., & Itô, H. (2002) · The Prostate · doi:10.1002/pros.10080 · Cited by 43
Boyd, D. D., Kim, S.-J., Wang, H., Jones, T. R., & Gallick, G. E. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63855-2 · Cited by 43
Molecular characterization of the loss of p75NTR expression in human prostate tumor cells
Krygier, S., & Djakiew, D. (2001) · Molecular Carcinogenesis · doi:10.1002/mc.1038 · Cited by 43
Self-citationHerrmann, J. L., Menter, D. G., Beham, A. W., von Eschenbach, A., & McDonnell, T. J. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3653 · Cited by 42
Flow cytometry as a predictive modality in prostate cancer
Deitch, A. D., & White, R. D. (1992) · Human Pathology · doi:10.1016/0046-8177(92)90081-d · Cited by 42
High fat diet increases the weight of rat ventral prostate
Cai, X., Haleem, R., Oram, S. W., Cyriac, J., Jiang, F., Grayhack, J. T., Kozlowski, J. M., & Wang, Z. (2001) · The Prostate · doi:10.1002/pros.1112 · Cited by 42
E‐cadherin and β‐catenin are down‐regulated in prostatic bone metastases
Bryden, A. A. G., Hoyland, J. A., Freemont, A. J., Clarke, N. W., Wismayer, D. S., & George, N. J. R. (2002) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.01712.x · Cited by 41
Soler, A. P., Harner, G. D., Knudsen, K. A., McBrearty, F. X., Grujić, E., Salazar, H., Han, A. C., & Keshgegian, A. A. (1997) · Europe PMC (PubMed Central) · Cited by 41
Crocitto, L. E., Henderson, B. E., & Coetzee, G. A. (1997) · PubMed · Cited by 41
Immunohistochemical localization of relaxin in human prostate.
Sokol, R. Z., Wang, X. S., Lechago, J., et al. (1989) · Journal of Histochemistry & Cytochemistry · doi:10.1177/37.8.2666509 · Cited by 41
Epidemiology of prostate cancer: molecular and environmental clues
Pienta, K. J., Goodson, J. A., & Esper, P. S. (1996) · Urology · doi:10.1016/s0090-4295(96)00219-1 · Cited by 41
Ghatak, S., & Ho, S. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0749 · Cited by 41
Self-citation
Research works printed but not linked: 902
- Oishi, 1995, Cancer Surv., 23, 267
- Parkin, 1992, IARC Sci Publ., 120, 45
- Doherty, 1996, Br J Hosp Med., 55, 104
- Morrison, 1995, Can J Public Health., 86, 274
- Dijkman, 1996, Eur Urol., 30, 281, 10.1159/000474185 · doi:10.1159/000474185
- Wingo, 1998, Cancer Epidemiol Biomarkers Prev., 7, 271
- Merrill, 1996, J Natl Cancer Inst., 88, 1683, 10.1093/jnci/88.22.1683 · doi:10.1093/jnci/88.22.1683
- Mettlin, 1996, Cancer., 77, 150, 10.1002/(SICI)1097-0142(19960101)77:1<150::AID-CNCR25>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19960101)77:1<150::aid-cncr25>3.0.co;2-3
- Brawley, 1997, Cancer., 80, 1857, 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19971101)80:9<1857::aid-cncr26>3.0.co;2-3
- Wingo, 1997, Cancer., 80, 1810, 10.1002/(SICI)1097-0142(19971101)80:9<1810::AID-CNCR19>3.0.CO;2-8 · doi:10.1002/(sici)1097-0142(19971101)80:9<1810::aid-cncr19>3.0.co;2-8
- Levy, 1993, CMAJ., 149, 617
- Smart, 1997, CA Cancer J Clin., 47, 134, 10.3322/canjclin.47.3.134 · doi:10.3322/canjclin.47.3.134
- Pienta, 1995, Urology., 45, 93, 10.1016/S0090-4295(95)96996-9 · doi:10.1016/s0090-4295(95)96996-9
- Dhom, 1983, J Cancer Res Clin Oncol., 106, 210, 10.1007/BF00402610 · doi:10.1007/bf00402610
- Polednak, 1997, Cancer., 79, 99, 10.1002/(SICI)1097-0142(19970101)79:1<99::AID-CNCR14>3.0.CO;2-1 · doi:10.1002/(sici)1097-0142(19970101)79:1<99::aid-cncr14>3.0.co;2-1
- Newman, 1996, Radiol Technol., 68, 39
- Bostwick, 1992, Cancer., 70, 291, 10.1002/1097-0142(19920701)70:1+<291::AID-CNCR2820701317>3.0.CO;2-4 · doi:10.1002/1097-0142(19920701)70:1+<291::aid-cncr2820701317>3.0.co;2-4
- Partin, 1994, Urology., 44, 646, 10.1016/S0090-4295(94)80197-5 · doi:10.1016/s0090-4295(94)80197-5
- Bostwick, 2000, Curr Urol Rep., 1, 65, 10.1007/s11934-000-0037-x · doi:10.1007/s11934-000-0037-x
- Bostwick, 1987, Cancer., 59, 788, 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I · doi:10.1002/1097-0142(19870215)59:4<788::aid-cncr2820590421>3.0.co;2-i
- Montironi, 1996, Eur Urol., 30, 133, 10.1159/000474162 · doi:10.1159/000474162
- Allam, 1996, Mod Pathol., 9, 742
- Qian, 1997, Hum Pathol., 28, 143, 10.1016/S0046-8177(97)90097-6 · doi:10.1016/s0046-8177(97)90097-6
- Feneley, 1997, Prostate Cancer Prostatic Dis., 1, 79, 10.1038/sj.pcan.4500210 · doi:10.1038/sj.pcan.4500210
- Sakr, 1997, Eur Urol., 32, 15
- Keetch, 1995, J Urol., 154, 347, 10.1016/S0022-5347(01)67044-7 · doi:10.1016/s0022-5347(01)67044-7
- Raviv, 1996, Acta Urol Belgium., 64, 11
- Rovner, 1997, J Urol., 158, 138, 10.1097/00005392-199707000-00042 · doi:10.1097/00005392-199707000-00042
- Davidson, 1995, J Urol., 154, 1295, 10.1016/S0022-5347(01)66840-X · doi:10.1016/s0022-5347(01)66840-x
- Shepherd, 1996, J Urol., 156, 460, 10.1016/S0022-5347(01)65881-6 · doi:10.1016/s0022-5347(01)65881-6
- Langer, 1996, J Urol., 155, 228, 10.1016/S0022-5347(01)66601-1 · doi:10.1016/s0022-5347(01)66601-1
- Bostwick, 1996, Eur Urol., 30, 145, 10.1159/000474164 · doi:10.1159/000474164
- Bostwick, 1996, Cancer., 78, 330, 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO;2-W · doi:10.1002/(sici)1097-0142(19960715)78:2<330::aid-cncr22>3.0.co;2-w
- Ferguson, 1994, Urology., 44, 91, 10.1016/S0090-4295(94)80015-4 · doi:10.1016/s0090-4295(94)80015-4
- Aquilina, 1997, J Natl Cancer Inst., 89, 689, 10.1093/jnci/89.10.689 · doi:10.1093/jnci/89.10.689
- Colombel, 1993, Am J Pathol., 143, 390
- Goldstein, 1995, Hum Pathol., 26, 887, 10.1016/0046-8177(95)90012-8 · doi:10.1016/0046-8177(95)90012-8
- Saez, 1998, Mod Pathol., 11, 1193
- Papadopoulos, 2001, Clin Cancer Res., 7, 1533
- Kirschenbaum, 1999, Mol Urol., 3, 163
- Molberg, 1994, Am J Clin Pathol., 101, 266, 10.1093/ajcp/101.3.266 · doi:10.1093/ajcp/101.3.266
- Shah, 2001, Arch Pathol Lab Med., 125, 141, 10.5858/2001-125-0141-HAHCOS · doi:10.5858/2001-125-0141-hahcos
- Bostwick, 1995, Arch Pathol Lab Med., 119, 444
- Varma, 2002, Arch Pathol Lab Med., 126, 554, 10.5858/2002-126-0554-MCFTDO · doi:10.5858/2002-126-0554-mcftdo
- Egan, 1997, Am J Surg Pathol., 21, 931, 10.1097/00000478-199708000-00007 · doi:10.1097/00000478-199708000-00007
- Zhou, 2001, Am J Clin Pathol., 115, 39, 10.1309/2APJ-YKBD-97EH-67GW · doi:10.1309/2apj-ykbd-97eh-67gw
- Bonin, 1997, Cancer., 79, 75, 10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19970101)79:1<75::aid-cncr11>3.0.co;2-3
- Ozcan, 2001, Eur Urol., 40, 308, 10.1159/000049791 · doi:10.1159/000049791
- D'Amico, 2001, J Urol., 165, 126, 10.1097/00005392-200101000-00031 · doi:10.1097/00005392-200101000-00031
- Nelson, 2002, Urology., 59, 740, 10.1016/S0090-4295(02)01654-0 · doi:10.1016/s0090-4295(02)01654-0
- O'Malley, 2002, Urology., 59, 85, 10.1016/S0090-4295(01)01486-8 · doi:10.1016/s0090-4295(01)01486-8
- Freedland, 2002, J Urol., 167, 516, 10.1016/S0022-5347(01)69076-1 · doi:10.1016/s0022-5347(01)69076-1
- Sebo, 2001, Cancer., 91, 2196, 10.1002/1097-0142(20010601)91:11<2196::AID-CNCR1249>3.0.CO;2-# · doi:10.1002/1097-0142(20010601)91:11<2196::aid-cncr1249>3.0.co;2-#
- Merrick, 2002, Cancer J., 8, 79, 10.1097/00130404-200201000-00014 · doi:10.1097/00130404-200201000-00014
- Bahnson, 1989, Prostate., 15, 149, 10.1002/pros.2990150208 · doi:10.1002/pros.2990150208
- Montironi, 1993, Virchows Arch A Pathol Anat Histopathol., 422, 185, 10.1007/BF01621801 · doi:10.1007/bf01621801
- Weidner, 1993, Am J Pathol., 143, 401
- Brawer, 1994, Cancer., 73, 678, 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO;2-6 · doi:10.1002/1097-0142(19940201)73:3<678::aid-cncr2820730329>3.0.co;2-6
- Hall, 1994, Urology., 44, 869, 10.1016/S0090-4295(94)80173-8 · doi:10.1016/s0090-4295(94)80173-8
- Vesalainen, 1994, Anticancer Res., 14, 709
- Epstein, 2000, Urology., 56, 283, 10.1016/S0090-4295(00)00640-3 · doi:10.1016/s0090-4295(00)00640-3
- Silberman, 1997, Cancer., 79, 772, 10.1002/(SICI)1097-0142(19970215)79:4<772::AID-CNCR14>3.0.CO;2-X · doi:10.1002/(sici)1097-0142(19970215)79:4<772::aid-cncr14>3.0.co;2-x
- de la Taille, 2000, Am J Clin Pathol., 113, 555, 10.1309/02W2-KE50-PKEF-G2G4 · doi:10.1309/02w2-ke50-pkef-g2g4
- Stamey, 1999, JAMA., 281, 1395, 10.1001/jama.281.15.1395 · doi:10.1001/jama.281.15.1395
- van den Ouden, 1998, Urol Int., 60, 17, 10.1159/000030197 · doi:10.1159/000030197
- McNeal, 1996, Am J Surg Pathol., 20, 1351, 10.1097/00000478-199611000-00006 · doi:10.1097/00000478-199611000-00006
- Mehta, 2001, Clin Cancer Res., 7, 81
- Whittemore, 1995, Am J Epidemiol., 141, 732, 10.1093/oxfordjournals.aje.a117495 · doi:10.1093/oxfordjournals.aje.a117495
- Klein, 1998, Prostate Cancer Prostatic Dis., 1, 297, 10.1038/sj.pcan.4500257 · DOI
- Damber, 1998, Int J Cancer., 78, 293, 10.1002/(SICI)1097-0215(19981029)78:3<293::AID-IJC5>3.0.CO;2-Q · doi:10.1002/(sici)1097-0215(19981029)78:3<293::aid-ijc5>3.0.co;2-q
- Bratt, 1999, Eur J Cancer., 35, 272, 10.1016/S0959-8049(98)00358-X · doi:10.1016/s0959-8049(98)00358-x
- Cerhan, 1999, Cancer Epidemiol Biomarkers Prev., 8, 53
- Lightfoot, 2000, Ann Epidemiol., 10, 470, 10.1016/S1047-2797(00)00112-5 · doi:10.1016/s1047-2797(00)00112-5
- Kalish, 2000, Urology., 56, 803, 10.1016/S0090-4295(00)00780-9 · DOI
- Kotsis, 2002, J Urol., 167, 1659, 10.1016/S0022-5347(05)65173-7 · doi:10.1016/s0022-5347(05)65173-7
- Cotter, 2002, Prostate., 50, 216, 10.1002/pros.10051 · doi:10.1002/pros.10051
- Stone, 2003, Ethn Dis., 13, 233
- Gronberg, 1999, Cancer., 86, 477, 10.1002/(SICI)1097-0142(19990801)86:3<477::AID-CNCR16>3.0.CO;2-K · doi:10.1002/(sici)1097-0142(19990801)86:3<477::aid-cncr16>3.0.co;2-k
- Schuurman, 1999, Epidemiology., 10, 192, 10.1097/00001648-199903000-00020 · doi:10.1097/00001648-199903000-00020
- McLellan, 1995, CMAJ., 153, 895
- Staples, 2003, Cancer Causes Control., 14, 161, 10.1023/A:1023073203467 · doi:10.1023/a:1023073203467
- Matikainen, 1999, Clin Cancer Res., 5, 1275
- Thiessen, 1974, Cancer., 34, 1102, 10.1002/1097-0142(197410)34:4<1102::AID-CNCR2820340421>3.0.CO;2-5 · doi:10.1002/1097-0142(197410)34:4<1102::aid-cncr2820340421>3.0.co;2-5
- Anderson, 1992, J Natl Cancer Inst., 84, 1114, 10.1093/jnci/84.14.1114 · doi:10.1093/jnci/84.14.1114
- Andrieu, 1991, Eur J Cancer., 27, 244, 10.1016/0277-5379(91)90506-9 · doi:10.1016/0277-5379(91)90506-9
- Henderson, 1982, Cancer Res., 42, 3232
- Ghanadian, 1979, Br J Cancer., 39, 696, 10.1038/bjc.1979.122 · doi:10.1038/bjc.1979.122
- Vatten, 1997, Cancer Epidemiol Biomarkers Prev., 6, 967
- Nomura, 1996, Cancer Epidemiol Biomarkers Prev., 5, 621
- Guess, 1997, Cancer Epidemiol Biomarkers Prev., 6, 21
- Chang, 2001, Prostate., 46, 62, 10.1002/1097-0045(200101)46:1<62::AID-PROS1009>3.0.CO;2-V · doi:10.1002/1097-0045(200101)46:1<62::aid-pros1009>3.0.co;2-v
- Stattin, 2001, J Clin Endocrinol Metab., 86, 1341
- Ross, 1986, J Natl Cancer Inst., 76, 45
- Barrett-Connor, 1990, Cancer Res., 50, 169
- Jackson, 1981, Progr Clin Biol Res., 53, 111
- Modugno, 2001, Clin Cancer Res., 7, 3092
- Haenszel, 1968, J Natl Cancer Inst., 40, 43
- Locke, 1980, J Natl Cancer Inst., 65, 1149
- Stellman, 1994, Cancer., 73, 1270, 10.1002/1097-0142(19940215)73:4<1270::AID-CNCR2820730423>3.0.CO;2-Y · doi:10.1002/1097-0142(19940215)73:4<1270::aid-cncr2820730423>3.0.co;2-y
- Merrill, 2000, Urology., 55, 730, 10.1016/S0090-4295(99)00564-6 · doi:10.1016/s0090-4295(99)00564-6
- Abdalla, 1998, Semin Urol Oncol., 16, 207
- Asbell, 2000, J Natl Med Assoc., 92, 445
- Zhang, 2000, J Urol., 163, 131, 10.1016/S0022-5347(05)67988-8 · doi:10.1016/s0022-5347(05)67988-8
- Fowler, 2000, J Urol., 163, 1467, 10.1016/S0022-5347(05)67644-6 · doi:10.1016/s0022-5347(05)67644-6
- Wu, 2001, Cancer Epidemiol Biomarkers Prev., 10, 533
- Reichardt, 1995, Cancer Res., 55, 3973
- Platz, 1999, Cancer Epidemiol Biomarkers Prev., 8, 1107
- Winter, 2001, Urology., 58, 614, 10.1016/S0090-4295(01)01273-0 · doi:10.1016/s0090-4295(01)01273-0
- Ekman, 1999, Prostate., 39, 262, 10.1002/(SICI)1097-0045(19990601)39:4<262::AID-PROS6>3.0.CO;2-P · doi:10.1002/(sici)1097-0045(19990601)39:4<262::aid-pros6>3.0.co;2-p
- Corder, 1995, Cancer Epidemiol Biomarkers Prev., 4, 655
- Yamada, 2001, Int J Cancer., 92, 683, 10.1002/1097-0215(20010601)92:5<683::AID-IJC1255>3.0.CO;2-4 · doi:10.1002/1097-0215(20010601)92:5<683::aid-ijc1255>3.0.co;2-4
- Leadon, 1990, Health Phys., 59, 15, 10.1097/00004032-199007000-00001 · doi:10.1097/00004032-199007000-00001
- Statland, 1992, Clin Chem., 38, 1587
- Palmiter, 1987, Experientia., 52, 63
- Yu, 1994, Cancer., 73, 596, 10.1002/1097-0142(19940201)73:3<596::AID-CNCR2820730316>3.0.CO;2-N · doi:10.1002/1097-0142(19940201)73:3<596::aid-cncr2820730316>3.0.co;2-n
- Hietanen, 1994, Eur J Clin Nutr., 48, 575
- Hietanen, 1991, Carcinogenesis., 12, 591, 10.1093/carcin/12.4.591 · doi:10.1093/carcin/12.4.591
- Clark, 1996, JAMA., 276, 1957, 10.1001/jama.1996.03540240035027 · DOI · Paper page
- Han, 1995, Carcinogenesis., 16, 951, 10.1093/carcin/16.4.951 · doi:10.1093/carcin/16.4.951
- Schuurman, 1999, Cancer., 86, 1019, 10.1002/(SICI)1097-0142(19990915)86:6<1019::AID-CNCR18>3.0.CO;2-H · doi:10.1002/(sici)1097-0142(19990915)86:6<1019::aid-cncr18>3.0.co;2-h
- Berg, 1975, Cancer Res., 35, 3345
- Blair, 1978, J Natl Cancer Inst., 61, 1379
- Ohno, 1988, Cancer Res., 48, 1331
- Mettlin, 1989, Cancer., 64, 605, 10.1002/1097-0142(19890801)64:3<605::AID-CNCR2820640307>3.0.CO;2-I · doi:10.1002/1097-0142(19890801)64:3<605::aid-cncr2820640307>3.0.co;2-i
- Hayes, 1999, Cancer Epidemiol Biomarkers Prev., 8, 25
- Graham, 1983, J Natl Cancer Inst., 70, 687
- Ross, 1987, J Natl Cancer Inst., 78, 869
- Severson, 1989, Cancer Res., 49, 1857
- Mills, 1989, Cancer., 64, 598, 10.1002/1097-0142(19890801)64:3<598::AID-CNCR2820640306>3.0.CO;2-6 · doi:10.1002/1097-0142(19890801)64:3<598::aid-cncr2820640306>3.0.co;2-6
- Hirayama, 1979, Natl Cancer Inst Monogr., 53, 149
- Hsing, 1990, Cancer Res., 50, 6836
- De Stefani, 2000, Cancer Epidemiol Biomarkers Prev., 9, 335
- Harvei, 1997, Int J Cancer., 71, 545, 10.1002/(SICI)1097-0215(19970516)71:4<545::AID-IJC7>3.0.CO;2-U · doi:10.1002/(sici)1097-0215(19970516)71:4<545::aid-ijc7>3.0.co;2-u
- Bishop, 1988, Immunogenetics., 28, 184, 10.1007/BF00375858 · doi:10.1007/bf00375858
- Sporn, 1984, J Natl Cancer Inst., 73, 1381
- Kummet, 1983, Semin Oncol., 10, 281
- Olsen, 1996, Ugeskr Laeger., 158, 3171
- Kolonel, 1987, Cancer Res., 47, 2982
- Ellison, 1998, Chron Dis Can., 19, 1
- Paganini-Hill, 1987, J Natl Cancer Inst., 79, 443
- Hayes, 1988, Cancer., 62, 2021, 10.1002/1097-0142(19881101)62:9<2021::AID-CNCR2820620925>3.0.CO;2-R · doi:10.1002/1097-0142(19881101)62:9<2021::aid-cncr2820620925>3.0.co;2-r
- Reichman, 1990, Cancer Res., 50, 2311
- Wald, 1986, Br J Cancer., 54, 957, 10.1038/bjc.1986.267 · doi:10.1038/bjc.1986.267
- Nomura, 1997, Cancer Epidemiol Biomarkers Prev., 6, 487
- Cook, 1999, Cancer., 86, 1783, 10.1002/(SICI)1097-0142(19991101)86:9<1783::AID-CNCR21>3.0.CO;2-N · doi:10.1002/(sici)1097-0142(19991101)86:9<1783::aid-cncr21>3.0.co;2-n
- Lu, 2001, Cancer Epidemiol Biomarkers Prev., 10, 749
- Hirayama, 1986, Gan No Rinsho., 32, 610
- Clinton, 1999, Cancer., 86, 1629, 10.1002/(SICI)1097-0142(19991101)86:9<1629::AID-CNCR1>3.0.CO;2-4 · doi:10.1002/(sici)1097-0142(19991101)86:9<1629::aid-cncr1>3.0.co;2-4
- Eichholzer, 1999, Prostate., 38, 189, 10.1002/(SICI)1097-0045(19990215)38:3<189::AID-PROS3>3.0.CO;2-N · doi:10.1002/(sici)1097-0045(19990215)38:3<189::aid-pros3>3.0.co;2-n
- Schwartz, 1990, Anticancer Res., 10, 1307
- Corder, 1993, Cancer Epidemiol Biomarkers Prev., 2, 467
- Peehl, 1999, Eur Urol., 35, 392, 10.1159/000019914 · doi:10.1159/000019914
- Suzuki, 2003, Int J Urol., 10, 261, 10.1046/j.1442-2042.2003.00617.x · doi:10.1046/j.1442-2042.2003.00617.x
- Schwartz, 1998, Cancer Epidemiol Biomarkers Prev., 7, 391
- Gann, 1996, Cancer Epidemiol Biomarkers Prev., 5, 121
- Schwartz, 1994, Anticancer Res., 14, 1077
- Chan, 1999, Cancer Epidemiol Biomarkers Prev., 8, 893
- Liang, 1999, Prostate., 40, 200, 10.1002/(SICI)1097-0045(19990801)40:3<200::AID-PROS8>3.0.CO;2-3 · doi:10.1002/(sici)1097-0045(19990801)40:3<200::aid-pros8>3.0.co;2-3
- Feustel, 1986, Prostate., 8, 75, 10.1002/pros.2990080109 · doi:10.1002/pros.2990080109
- Leake, 1984, Acta Endocrinol (Copenhagen)., 105, 281, 10.1530/acta.0.1050281 · doi:10.1530/acta.0.1050281
- Whelan, 1983, Br J Urol., 55, 525, 10.1111/j.1464-410X.1983.tb03362.x · doi:10.1111/j.1464-410x.1983.tb03362.x
- Chirulescu, 1987, Med Interne., 25, 257
- Ogunlewe, 1989, Cancer., 63, 1388, 10.1002/1097-0142(19890401)63:7<1388::AID-CNCR2820630725>3.0.CO;2-M · doi:10.1002/1097-0142(19890401)63:7<1388::aid-cncr2820630725>3.0.co;2-m
- Lekili, 1991, Int Urol Nephrol., 23, 151, 10.1007/BF02549712 · doi:10.1007/bf02549712
- McCallum, 1988, Br J Urol., 62, 565, 10.1111/j.1464-410X.1988.tb04427.x · doi:10.1111/j.1464-410x.1988.tb04427.x
- Feustel, 1989, Urol Res., 17, 41
- Tvedt, 1989, Prostate., 15, 41, 10.1002/pros.2990150105 · doi:10.1002/pros.2990150105
- Elghany, 1990, Epidemiology., 1, 107, 10.1097/00001648-199003000-00005 · doi:10.1097/00001648-199003000-00005
- Goodman, 2001, Cancer Epidemiol Biomarkers Prev., 10, 1069
- Nomura, 2000, Cancer Epidemiol Biomarkers Prev., 9, 883
- Grant, 1999, Altern Med Rev., 4, 162
- Rodriguez, 2003, Cancer Epidemiol Biomarkers Prev., 12, 597
- Balaji, 2001, Prostate., 48, 265, 10.1002/pros.1106 · doi:10.1002/pros.1106
- Sung, 1999, Cancer., 86, 484, 10.1002/(SICI)1097-0142(19990801)86:3<484::AID-CNCR17>3.0.CO;2-P · doi:10.1002/(sici)1097-0142(19990801)86:3<484::aid-cncr17>3.0.co;2-p
- Hsieh, 1999, Int J Cancer., 80, 699, 10.1002/(SICI)1097-0215(19990301)80:5<699::AID-IJC12>3.0.CO;2-7 · doi:10.1002/(sici)1097-0215(19990301)80:5<699::aid-ijc12>3.0.co;2-7
- van der Gulden, 1994, Br J Urol., 73, 382, 10.1111/j.1464-410X.1994.tb07601.x · doi:10.1111/j.1464-410x.1994.tb07601.x
- Kolonel, 1977, Lancet., 2, 566, 10.1016/S0140-6736(77)90714-0 · doi:10.1016/s0140-6736(77)90714-0
- Schuman, 1977, Cancer Treat Rep., 61, 181
- Niijima, 1980, Scand J Urol Nephrol., 55, 177
- Newell, 1998, Vet Radiol Ultrasound., 39, 332, 10.1111/j.1740-8261.1998.tb01616.x · doi:10.1111/j.1740-8261.1998.tb01616.x
- Talamini, 1993, Prev Med., 22, 400, 10.1006/pmed.1993.1033 · doi:10.1006/pmed.1993.1033
- Hayes, 1994, Cancer Causes Control., 5, 221, 10.1007/BF01830240 · doi:10.1007/bf01830240
- Lumey, 1997, Prostate., 33, 195, 10.1002/(SICI)1097-0045(19971101)33:3<195::AID-PROS8>3.0.CO;2-I · doi:10.1002/(sici)1097-0045(19971101)33:3<195::aid-pros8>3.0.co;2-i
- Giles, 2001, Ann Oncol., 12, 761, 10.1023/A:1011131105617 · doi:10.1023/a:1011131105617
- Plaskon, 2003, Cancer Epidemiol Biomarkers Prev., 12, 604
- Lotufo, 2000, Int J Cancer., 87, 141, 10.1002/1097-0215(20000701)87:1<141::AID-IJC21>3.0.CO;2-A · doi:10.1002/1097-0215(20000701)87:1<141::aid-ijc21>3.0.co;2-a
- Whittemore, 1985, J Natl Cancer Inst., 74, 43
- Carstensen, 1987, J Epidemiol Commun Health., 41, 166, 10.1136/jech.41.2.166 · DOI
- Giovannucci, 1999, Cancer Epidemiol Biomarkers Prev., 8, 277
- Colditz, 1996, Cancer Causes Control., 7, 560, 10.1007/BF00051890 · doi:10.1007/bf00051890
- Yu, 1997, Cancer Detect Prev., 21, 497
- Verhoeven, 1996, Cancer Epidemiol Biomarkers Prev., 5, 733
- Schuurman, 1998, Cancer Epidemiol Biomarkers Prev., 7, 673
- Kolonel, 2000, Cancer Epidemiol Biomarkers Prev., 9, 795
- Lee, 2003, Cancer Epidemiol Biomarkers Prev., 12, 665
- Gann, 1999, Cancer Res., 59, 1225
- Clinton, 1996, Cancer Epidemiol Biomarkers Prev., 5, 823
- Imaida, 2001, Carcinogenesis., 22, 467, 10.1093/carcin/22.3.467 · doi:10.1093/carcin/22.3.467
- Watson, 1995, Environ Health Perspect., 103, 41
- Soto, 1995, Environ Health Perspect., 103, 113
200 of 902 shown
Cited by
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies
Hormones, E. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm323 · Cited by 786
Tang, W.-Y., Morey, L. M., Cheung, Y. Y., Birch, L., Prins, G. S., & Ho, S.-M. (2012) · Endocrinology · doi:10.1210/en.2011-1308 · Cited by 164
Self-citationBarrington, W. E., Schenk, J. M., Etzioni, R., Arnold, K. B., Neuhouser, M. L., Thompson, I. M., Lucia, M. S., & Kristal, A. R. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0513 · Cited by 107
Metadata
- Authors
- Bostwick, D. G., Burke, H. B., Djakiew, D., Euling, S., Ho, S.-M., Landolph, J., Morrison, H., Sonawane, B., Shifflett, T., Waters, D. J., & Timms, B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004
- Volume
- 101
- Issue
- S10
- Pages
- 2371-2490
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2121518362
- Cited by
- 650
- References
- 914
- FWCI
- 18.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4261 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.